Gilead Stock News

DNB Asset Management AS cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 316,814 shares of the biopharmaceutical companys stock after selling 651 shares during the quarter. DNB Asset Management ASs []

Twin Lakes Capital Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,822 shares of the biopharmaceutical companys stock after purchasing an additional 472 shares during the quarter. Gilead Sciences []

Pacer Advisors Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 419,503 shares of the biopharmaceutical companys stock after purchasing an additional 52,013 shares during the period. Pacer Advisors Inc.s holdings in Gilead Sciences []

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Crossmark Global Holdings Inc. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 77.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 44,058 shares of the biopharmaceutical companys stock after selling 151,608 shares during the quarter. Crossmark Global Holdings []

Brokerages expect that Gilead Sciences, Inc. (NASDAQ:GILD) will announce $6.39 billion in sales for the current quarter, Zacks reports. Seven analysts have issued estimates for Gilead Sciences earnings. The lowest sales estimate is $6.22 billion and the highest is $6.69 billion. Gilead Sciences reported sales of $7.42 billion during the same quarter last year, which []

Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More

Global Small Molecule Sterile Injectable Drugs Market Overview: A brilliant Small Molecule Sterile Injectable Drugs Market research report brings into focus the key market dynamics of the sector. This market study also analyzes the market status, market share, growth rate, future

If you want dividend growth, dividend safety, and an undervalued stock, these three fit the bill.

Hixon Zuercher LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 15,862 shares of the biopharmaceutical company’s stock after acquiring an additional 287 shares during the period. Hixon Zuercher LLC’s holdings in Gilead Sciences were worth $1,108,000 as of its […]

The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.

Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players

Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV i

The European Commission has approved Gilead Sciences Inc''s (NASDAQ: GILD ) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (TNBC). The approval for the antibody-drug conjugate covers adult patients with unresectable or metastatic TNBC who have received two or more Full story available on Benzinga.com